Edward B. Garon, MD | Authors


IMpower150 Data for Immunotherapy Quadruplet in EGFR-Mutant Lung Cancer

February 05, 2019

Edward B. Garon, MD, discusses data from the IMpower150 trial where patients with EGFR-mutant lung cancer were randomized to 1 of 3 arms: a control of carboplatin, paclitaxel, and bevacizumab (Avastin), an arm replacing bevacizumab with atezolizumab (Tecentriq), and a third using all 4 agents.